We are live on ! Find out more

Regenxbio

RGNX

Market cap $574M

8.69 USD

+0.16

1.88%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

8.76

+0.07

0.81%

1 day

1.88%

5 days

-2.91%

1 month

-19.31%

3 months

22.91%

6 months

-1.14%

Year to date

-35.96%

1 year

-4.4%

5 years

-80.98%

10 years

-38.72%

About: Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

Employees: 371

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 32.3%

Neutral 51.6%

Negative 16.1%

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Sept. 8, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Baird 2026 Global Healthcare Conference Fireside Chat: Tuesday, September 15 at 8:30 a.m.

REGENXBIO to Participate in Upcoming Investor Conferences

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)

SAN DIEGO--(BUSINESS WIRE)---- $RGNX #BiotechInvesting--Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of REGENXBIO Inc. (NASDAQ: RGNX) against certain of its officers and directors for alleged breaches of fiduciary duty. Shareholders who have held REGENXBIO shares continuously since prior to February 9, 2022, may have standing to seek corporate governance reforms, the return of funds to the Company, and a court-approved incentive award, all at no cost to them. What Sho.

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)

Zacks Investment Research

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity

Regenxbio is rated a 'risky buy' due to high volatility, regulatory setbacks, and significant near-term catalysts. RGNX faces a clinical hold on RGX-121 for Hunter Syndrome, complicating milestone payments and royalty streams, but maintains sufficient cash runway into Q4 2027. Pivotal data for the AbbVie-partnered eye disease program and BLA submission for RGX-202 in DMD represent major binary catalysts by year-end and 2027.

Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026.

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold

SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating REGENXBIO Inc. (NASDAQ: RGNX) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws. If you purchased REGENXBIO securities and suffered losses, click here to join the investigation.

RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company's investigational therapy for Hunter syndome.

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome

Regenxbio said on Monday the U.S. Food ‌and Drug Administration has placed its experimental gene therapy for Hunter syndrome on clinical hold after spinal scans found abnormalities ⁠in five study participants.

FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome.

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade)

Regenxbio Inc. delivered a strong quarter, driven by milestone revenue, with GAAP EPS of $0.43 and revenue up 407% YoY. RGNX now holds $313 million in pro forma cash, funding operations into Q4 2027 and removing near-term financing overhang. Multiple late-stage catalysts—including RGX-202, pivotal wet AMD data, and RGX-121 resubmission—are stacked over the next 12–18 months.

Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade)

See News Rankings

Price charts implemented using Lightweight Charts™